ArriVent BioPharma Quarterly Balance Sheet
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 16.50 -1.37%
ArriVent BioPharma financial position
As of Jun 30, 2026, ArriVent BioPharma reported total assets of $394.7 million, up 46.5% from a year earlier against total liabilities of $27.9 million. Shareholders' equity stood at $366.8 million, or 92.9% of assets. The company held $154.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 14.16, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
ArriVent BioPharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 154.68M | 62.10M | 45.54M | 112.67M | 112.77M | 49.87M | 74.29M | 282.86M | 298.67M | 317.39M | 150.39M | 141.36M |
| Short-Term Investments | 218.44M | 264.28M | 267.28M | 187.59M | 122.92M | 126.21M | 144.57M | — | — | — | — | — |
| Total Current Assets | 394.17M | 348.70M | 332.90M | 321.22M | 250.15M | 185.78M | 226.98M | 292.40M | 308.51M | 327.48M | 159.97M | — |
| Long-Term Investments | — | — | — | 5.11M | 18.79M | 29.41M | 47.68M | — | — | — | — | — |
| Total Assets | 394.72M | 349.30M | 333.17M | 326.56M | 269.51M | 215.50M | 274.94M | 292.71M | 308.86M | 327.84M | 163.10M | — |
| Accounts Payable | 2.22M | 8.73M | 5.93M | 5.93M | 4.06M | 4.36M | 3.78M | 4.65M | 3.81M | 4.10M | 4.53M | — |
| Total Current Liabilities | 27.84M | 25.00M | 25.95M | 21.56M | 19.64M | 12.95M | 17.27M | 15.16M | 12.10M | 9.98M | 11.62M | — |
| Total Liabilities | 27.88M | 25.32M | 25.95M | 21.56M | 19.64M | 12.95M | 17.29M | 15.22M | 12.20M | 10.12M | 11.80M | — |
| Shareholders' Equity | 366.84M | 323.98M | 307.22M | 305.00M | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M | 317.72M | -153.19M | -132.60M |
| Retained Earnings | -497.85M | -447.96M | -404.64M | -369.10M | -334.12M | -302.72M | -238.33M | -217.70M | -197.14M | -175.26M | -157.84M | — |
| Net Cash (Debt) | 373.12M | 326.38M | 312.82M | 300.27M | 235.69M | 176.08M | 218.86M | 282.86M | 298.67M | 317.39M | 150.39M | 141.36M |
| Shares Outstanding | 48.32M | 45.31M | 42.45M | 40.85M | 37.49M | 34.04M | 33.71M | 33.69M | 33.51M | 33.49M | 2.75M | — |
This table shows 12 quarterly periods of ArriVent BioPharma's balance sheet, from Q2 2026 back to Q3 2023, across 12 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow AVBP's reporting calendar. What is a balance sheet?